Latest news with #NovaSeqXSeries
Time of India
20 hours ago
- Business
- Time of India
Dr. Lal PathLabs adds Illumina's NovaSeq X Series to expand genomics capabilities
Mumbai: Diagnostic provider Dr. Lal PathLabs Limited (DLPL) has expanded its genomics division, Genevolve , with the addition of Illumina 's NovaSeq X Series . The integration is expected to enhance the lab's capacity to deliver faster and more accurate genomic insights . The NovaSeq X system incorporates Illumina's XLEAP-SBS chemistry, offering high throughput, improved accuracy, and increased efficiency. It is stated that The NovaSeq X Plus model can process over 20,000 whole genomes per year—more than twice the capacity of Illumina's earlier models. The system is designed to support large-scale genomic research through increased speed and sensitivity. According to DLPL, the investment supports its broader efforts to improve genomic testing capabilities and contribute to the country's growing genomics landscape. Launched in 2019, DLPL's Genevolve unit focuses on DNA-based diagnostics and next-generation sequencing (NGS). The addition of Illumina's technology is expected to further strengthen its offerings in this space. Dr. Lal PathLabs and Illumina also plan to collaborate with India's scientific and medical communities to promote awareness and capacity-building for genomics-based healthcare.
Business Standard
a day ago
- Business
- Business Standard
Dr Lal Pathlabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
Dr Lal Pathlabs (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, DLPL can now deliver faster and more accurate genomic research insights. The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements. With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence, said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape. Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing (NGS), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity.
Yahoo
21-05-2025
- Business
- Yahoo
Gene Expression Analysis Market Outlook 2025-2030: Overcoming Challenges such as Data Complexities and Cost Barriers
Key market opportunities include rising demand for personalized medicine driven by gene expression profiling, technological advancements such as high-throughput sequencing, and the adoption of single-cell RNA sequencing. These trends are expanding applications in oncology, personalized treatments, and biomedical research. Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "Gene Expression Analysis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to Gene Expression Analysis Market was valued at USD 5.02 Billion in 2024 and is projected to reach USD 7.84 Billion by 2030, rising at a CAGR of 7.71%. A key growth factor is the rising demand for personalized treatment approaches, where gene expression profiling helps identify individual genetic signatures, enabling more precise and effective therapies. Technological advancements, particularly in high-throughput sequencing platforms like RNA-Seq, have significantly enhanced researchers' ability to investigate the transcriptome at an unprecedented scale. The adoption of these technologies has fueled a surge in biomedical research and collaboration among pharmaceutical firms, diagnostic developers, and research institutions. In oncology, gene expression tools are increasingly used to discover biomarkers and predict treatment responses, further accelerating the expansion of the Market Driver: Advancements in Sequencing TechnologiesTechnological progress in sequencing has been a critical driver of the Global Gene Expression Analysis Market. Next-generation sequencing (NGS), in particular, has transformed gene expression studies by offering high-throughput capabilities, greater sensitivity, and cost efficiency. NGS enables the simultaneous examination of thousands of genes across numerous samples, providing deeper insights into gene activity and capabilities have broadened the use of gene expression profiling in personalized medicine, disease diagnostics, and fundamental research. The launch of high-capacity sequencers like Illumina's NovaSeq X Series, which can process over 20,000 whole genomes annually, exemplifies how enhanced throughput and reduced costs are making transcriptome analysis more accessible and widespread. This technological evolution is reshaping genomic research and reinforcing the market's long-term growth Market Challenge: Data Analysis ComplexitiesOne of the significant hurdles in the Global Gene Expression Analysis Market is the complexity involved in managing and interpreting large-scale gene expression data. High-throughput methods, such as RNA-Seq, generate vast volumes of data that require sophisticated bioinformatics tools and computational infrastructure for effective analysis. The necessity for robust data processing pipelines - from quality control and alignment to normalization and differential expression analysis - adds layers of technical difficulty. Missteps at any stage can lead to inaccurate conclusions, undermining research validity. Additionally, the requirement for high-performance computing resources and specialized data analytics expertise presents a cost and skill barrier for many institutions, especially smaller laboratories and emerging markets. Addressing these analytical challenges is vital for maximizing the utility and reliability of gene expression Market Trend: Single-Cell RNA Sequencing (scRNA-Seq)A prominent trend in the Global Gene Expression Analysis Market is the growing use of Single-Cell RNA Sequencing (scRNA-Seq). This cutting-edge technique enables researchers to profile gene expression at the individual cell level, revealing cellular heterogeneity that is otherwise masked in bulk RNA analyses. scRNA-Seq is transforming areas such as cancer biology, immunology, neuroscience, and developmental biology by allowing precise characterization of rare cell types and cellular states. This capability is driving a deeper understanding of disease mechanisms, progression, and treatment resistance. The rise of scRNA-Seq reflects a broader shift toward high-resolution, data-rich research tools that support more accurate and personalized scientific Players Profiled in this Gene Expression Analysis Market Report Merck KGaA Genscript Biotech Corporation Qiagen Bio-Rad Laboratories Takara Bio Inc. Thermo Fisher Scientific, Inc. Promega Corporation Agilent Technologies Lonza Group Ltd. New England Biolabs Inc Report ScopeIn this report, the Global Gene Expression Analysis Market has been segmented into the following categories:Gene Expression Analysis Market, by Product Type: Instruments Services Others Gene Expression Analysis Market, by Technique: RNA Expression Promotor Analysis Protein Expression & Post Translational Modification Expression Others Gene Expression Analysis Market, by Application: Drug Discovery and Development Clinical Diagnostics Biotechnology and Microbiology Others Gene Expression Analysis Market, by End User: Pharmaceutical and Biotechnology Companies Contract Research Organizations (CROs) Academic and Government Research Institutes Others Gene Expression Analysis Market, by Region: North America Europe Asia-Pacific South America Middle East & Africa Key Attributes Report Attribute Details No. of Pages 185 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $5.02 Billion Forecasted Market Value (USD) by 2030 $7.84 Billion Compound Annual Growth Rate 7.7% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
